HK1066818A1 - - Google Patents

Info

Publication number
HK1066818A1
HK1066818A1 HK04109894A HK04109894A HK1066818A1 HK 1066818 A1 HK1066818 A1 HK 1066818A1 HK 04109894 A HK04109894 A HK 04109894A HK 04109894 A HK04109894 A HK 04109894A HK 1066818 A1 HK1066818 A1 HK 1066818A1
Authority
HK
Hong Kong
Application number
HK04109894A
Inventor
Luis Enrique Fernandez Molina
Ana Maria Vazquez Lopez
Rolando Perez Rodriguez
Alexis Perez Gonzalez
Adriana Carr Perez
Yildian Diaz Rodriguez
Mauro A Alfonso Fernandez
Adriana Maria Rojas Del Calvo
Original Assignee
Ct De Inmunogogia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Inmunogogia Molecular filed Critical Ct De Inmunogogia Molecular
Publication of HK1066818A1 publication Critical patent/HK1066818A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK04109894A 2001-04-06 2004-12-14 HK1066818A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2001008420010084A CU23007A1 (es) 2001-04-06 2001-04-06 Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
PCT/CU2002/000002 WO2002081661A2 (es) 2001-04-06 2002-04-08 Combinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos

Publications (1)

Publication Number Publication Date
HK1066818A1 true HK1066818A1 (zh) 2005-04-01

Family

ID=40291118

Family Applications (3)

Application Number Title Priority Date Filing Date
HK04109894A HK1066818A1 (zh) 2001-04-06 2004-12-14
HK05102752A HK1070080A1 (en) 2001-04-06 2005-04-01 Ganglioside-associated recombinant antibodies and the use thereof in the preparation of medicament for the diagnosis and treatment of tumors
HK07114311.6A HK1109160A1 (en) 2001-04-06 2007-12-31 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK05102752A HK1070080A1 (en) 2001-04-06 2005-04-01 Ganglioside-associated recombinant antibodies and the use thereof in the preparation of medicament for the diagnosis and treatment of tumors
HK07114311.6A HK1109160A1 (en) 2001-04-06 2007-12-31 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours

Country Status (37)

Country Link
US (3) US20050069535A1 (zh)
EP (3) EP1798243B1 (zh)
JP (2) JP4366080B2 (zh)
KR (3) KR100946168B1 (zh)
CN (3) CN101054417B (zh)
AR (2) AR033123A1 (zh)
AT (3) ATE406386T1 (zh)
AU (3) AU2002308348B2 (zh)
BG (2) BG66304B1 (zh)
BR (3) BR0208675A (zh)
CA (2) CA2441845C (zh)
CU (1) CU23007A1 (zh)
CZ (2) CZ304424B6 (zh)
DE (2) DE60223547T2 (zh)
DK (2) DK1384726T3 (zh)
EA (2) EA006310B1 (zh)
EC (2) ECSP034788A (zh)
ES (2) ES2296986T3 (zh)
HK (3) HK1066818A1 (zh)
HR (2) HRP20030806B1 (zh)
HU (2) HU228105B1 (zh)
IL (2) IL158246A0 (zh)
IS (2) IS2701B (zh)
MX (2) MXPA03008739A (zh)
MY (3) MY145703A (zh)
NO (2) NO331533B1 (zh)
NZ (2) NZ528599A (zh)
PE (1) PE20020972A1 (zh)
PL (2) PL371770A1 (zh)
PT (2) PT1384726E (zh)
SG (1) SG161737A1 (zh)
SI (2) SI1384726T1 (zh)
SK (2) SK287914B6 (zh)
UA (3) UA75393C2 (zh)
UY (2) UY27243A1 (zh)
WO (2) WO2002081496A2 (zh)
ZA (2) ZA200307585B (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297336B2 (en) * 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
RU2396088C2 (ru) * 2005-02-04 2010-08-10 СУРВАК АпС Вакцина на основе пептидов сурвивина
FI20055398A0 (fi) * 2005-07-08 2005-07-08 Suomen Punainen Risti Veripalv Menetelmä solupopulaatioiden evaluoimiseksi
EP1919952B1 (en) 2005-08-11 2016-02-17 Matossian-Rogers Arpi Tcr-v-beta related peptides for treatment and diagnosis of autoimmune disease
WO2007024535A2 (en) * 2005-08-19 2007-03-01 Wyeth Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
ITFI20060163A1 (it) * 2006-06-29 2006-09-28 Menarini Internat Operations Luxembourg Sa Composizione farmaceutica contenente un anticorpo monoclonale anti idiotipico anti-ca-125 ed alluminio
TWI434855B (zh) * 2006-11-21 2014-04-21 Hoffmann La Roche 結合物及其在免疫分析中作為參考標準之用途
WO2009104649A1 (ja) * 2008-02-22 2009-08-27 片山化学工業株式会社 合成糖脂質含有リポソーム
EP2166085A1 (en) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
US9034324B2 (en) 2009-03-10 2015-05-19 Biogen Idec Ma Inc. Anti-BCMA antibodies
EP2414399A1 (en) 2009-04-01 2012-02-08 F. Hoffmann-La Roche AG Anti-fcrh5 antibodies and immunoconjugates and methods of use
CU23736A1 (es) * 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
WO2011026242A1 (en) * 2009-09-03 2011-03-10 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
AU2012205663B2 (en) * 2011-01-10 2017-02-02 Emory University Antibodies directed against influenza
CU24070B1 (es) * 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
EP2641916A1 (en) * 2012-03-23 2013-09-25 Centre National de la Recherche Scientifique (C.N.R.S) Novel antibodies anti-sPLA2-IIA and uses thereof
US8992913B2 (en) 2012-06-15 2015-03-31 Pfizer Inc. Antagonist antibodies against GDF-8 and uses therefor
AR096687A1 (es) 2013-06-24 2016-01-27 Genentech Inc Anticuerpos anti-fcrh5
WO2015095392A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Anti-cd3 antibodies and methods of use
KR101966408B1 (ko) * 2014-04-10 2019-04-05 오비아이 파머 인코퍼레이티드 항체，약학적 조성물 및 이의 용도
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
FI3310814T3 (fi) 2015-06-16 2023-09-21 Hoffmann La Roche HUMANISOITUJA JA AFFINITEETTIKYPSIÄ FcRH5-VASTA-AINEITA JA KÄYTTÖMENETELMIÄ
WO2018017864A2 (en) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
JP7126269B2 (ja) 2016-11-30 2022-08-26 メレオ バイオファーマ ５ インコーポレイテッド Ｔｉｇｉｔ結合物質を含む、がんの処置のための方法
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2754206B2 (ja) * 1987-11-17 1998-05-20 メクト株式会社 α２→３結合を認識するモノクローナル抗体
US6051225A (en) * 1988-10-19 2000-04-18 The Dow Chemical Company Family of high affinity, modified antibodies for cancer treatment
PT586002E (pt) * 1992-08-18 2000-07-31 Centro Inmunologia Molecular Anticorpos monoclonais que reconhecem o receptor do factor de crescimento epidermico, celulas e metodos para a sua producao e composicoes que os incluem
JPH07101999A (ja) * 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列
DE69428763T2 (de) * 1993-12-09 2002-08-01 Centro De Inmunologia Molecular, Ciudad De La Habana Monoklonale Antikörper gegen Ganglioside und deren Verwendung in der spezifischen, aktiven Immuntherapie gegen bösartige Tumoren
US6063379A (en) * 1993-12-09 2000-05-16 Centro De Inmunologia Molecular Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
CU22702A1 (es) * 1997-10-21 2001-07-31 Centro Inmunologia Molecular Anticuerpos monoclonales anti - idiotipo, su uso en la inmunoterapia activa de tumores malignos, hibridoma que los produce y composiciones que los contienen
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies

Also Published As

Publication number Publication date
JP4366080B2 (ja) 2009-11-18
CN1507452A (zh) 2004-06-23
US20040253233A1 (en) 2004-12-16
SK12162003A3 (sk) 2004-05-04
HUP0401355A3 (en) 2012-05-29
PT1384726E (pt) 2008-12-05
HU228106B1 (en) 2012-11-28
EA200301098A1 (ru) 2004-04-29
HK1070080A1 (en) 2005-06-10
US20100297008A1 (en) 2010-11-25
BR0208676B1 (pt) 2017-11-14
EP1384726A2 (en) 2004-01-28
HRP20030805B1 (en) 2011-11-30
US20050069535A1 (en) 2005-03-31
DE60228561D1 (de) 2008-10-09
ATE406386T1 (de) 2008-09-15
KR100919617B1 (ko) 2009-09-29
NZ528599A (en) 2005-03-24
NO20034437L (no) 2003-12-02
UA86768C2 (ru) 2009-05-25
KR20030092048A (ko) 2003-12-03
EP1798243A2 (en) 2007-06-20
IL158246A0 (en) 2004-05-12
IS6965A (is) 2003-09-23
HUP0401695A3 (en) 2012-05-29
JP2004525953A (ja) 2004-08-26
NO20034436D0 (no) 2003-10-03
PL208109B1 (pl) 2011-03-31
PL371937A1 (en) 2005-07-11
SK287914B6 (sk) 2012-03-02
CZ20032641A3 (cs) 2004-07-14
ZA200307679B (en) 2005-03-30
MY157372A (en) 2016-06-15
CA2441845C (en) 2011-06-07
HUP0401695A2 (en) 2006-08-28
EA006310B1 (ru) 2005-10-27
SG161737A1 (en) 2010-06-29
CZ20032668A3 (cs) 2004-07-14
AU2007231687B2 (en) 2010-09-30
HRP20030806B1 (en) 2011-11-30
EP1798243A3 (en) 2007-10-17
PT1411064E (pt) 2008-02-12
EP1798243B1 (en) 2010-08-11
MXPA03008739A (es) 2003-12-11
WO2002081496A3 (es) 2004-02-19
UA76745C2 (uk) 2006-09-15
HUP0401355A2 (hu) 2004-10-28
PL371770A1 (en) 2005-06-27
KR100946168B1 (ko) 2010-03-11
EP1384726B1 (en) 2008-08-27
IS6964A (is) 2003-09-23
MXPA03008738A (es) 2003-12-11
JP2004528033A (ja) 2004-09-16
ECSP034788A (es) 2004-01-28
KR20030087053A (ko) 2003-11-12
WO2002081661A2 (es) 2002-10-17
SK12262003A3 (sk) 2004-08-03
AR033122A1 (es) 2003-12-03
UY27243A1 (es) 2002-09-30
HRP20030806A2 (en) 2005-08-31
MY145703A (en) 2012-03-30
ATE378356T1 (de) 2007-11-15
HK1109160A1 (en) 2008-05-30
SK287783B6 (sk) 2011-09-05
ES2312610T3 (es) 2009-03-01
US8758753B2 (en) 2014-06-24
BR0208676A (pt) 2008-04-08
NO331533B1 (no) 2012-01-23
BG108228A (bg) 2005-04-30
CN1535282A (zh) 2004-10-06
IL158246A (en) 2010-05-31
DE60223547T2 (de) 2008-09-18
CZ304424B6 (cs) 2014-04-30
DK1411064T3 (da) 2008-03-25
BG108227A (bg) 2005-04-30
NZ528598A (en) 2005-03-24
ATE477279T1 (de) 2010-08-15
KR100863509B1 (ko) 2008-10-15
ES2296986T3 (es) 2008-05-01
AU2002308348B2 (en) 2007-11-22
WO2002081661A3 (es) 2003-01-03
CZ296276B6 (cs) 2006-02-15
WO2002081496A2 (es) 2002-10-17
AU2002308347B2 (en) 2006-09-14
CA2443372C (en) 2013-05-28
SI1411064T1 (sl) 2008-04-30
CA2443372A1 (en) 2002-10-17
PE20020972A1 (es) 2003-01-02
NO20034436L (no) 2003-12-02
IS2701B (is) 2010-11-15
BG66304B1 (bg) 2013-03-29
CN101054417B (zh) 2012-07-11
AR033123A1 (es) 2003-12-03
CN1319991C (zh) 2007-06-06
BR0208675A (pt) 2004-08-03
HRP20030805A2 (en) 2005-08-31
ECSP034787A (es) 2004-01-28
CA2441845A1 (en) 2002-10-17
CN101054417A (zh) 2007-10-17
EA200301097A1 (ru) 2004-02-26
EP1411064B1 (en) 2007-11-14
HU228105B1 (en) 2012-11-28
KR20080080680A (ko) 2008-09-04
MY137078A (en) 2008-12-31
UA75393C2 (en) 2006-04-17
EP1411064A2 (en) 2004-04-21
ZA200307585B (en) 2004-09-16
CU23007A1 (es) 2004-12-17
UY27242A1 (es) 2002-07-31
DK1384726T3 (da) 2008-12-15
DE60223547D1 (de) 2007-12-27
BRPI0208675B1 (pt) 2018-03-13
NO20034437D0 (no) 2003-10-03
AU2007231687A1 (en) 2007-11-22
CN100349920C (zh) 2007-11-21
BG66293B1 (en) 2013-02-28
EA006936B1 (ru) 2006-06-30
SI1384726T1 (sl) 2009-04-30

Similar Documents

Publication Publication Date Title
BE2022C531I2 (zh)
BE2022C502I2 (zh)
BE2022C547I2 (zh)
BE2017C056I2 (zh)
BE2017C051I2 (zh)
BE2017C032I2 (zh)
BE2016C051I2 (zh)
BE2015C046I2 (zh)
BE2014C052I2 (zh)
BE2014C036I2 (zh)
BE2014C026I2 (zh)
BE2014C006I2 (zh)
BE2017C050I2 (zh)
JP2002023029A5 (zh)
JP2002112972A5 (zh)
JP2002096607A5 (zh)
BRPI0209186B1 (zh)
JP2002246698A5 (zh)
BE2014C008I2 (zh)
CH1379220H1 (zh)
BRPI0204884B1 (zh)
BE2016C021I2 (zh)
BE2017C059I2 (zh)
DE60237177D1 (zh)
BRPI0101486B8 (zh)

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE NAME OF THE INVENTOR FROM DRIANA CARR PEREZ TO ADRIANA CARR PEREZ

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180408